HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schaefer, E. J. Articles by Brewer, H. B. Search for Related Content PubMed PubMed Citation Articles by Schaefer, E. J. Articles by Brewer, H. B., Jr Social Bookmarking                      What's this?

Journal of Lipid Research, Vol 22, 217-228, Copyright © 1981 by Lipid Research, Inc.

ARTICLES

Metabolism of high density lipoprotein subfractions and constituents in Tangier disease following the infusion of high density lipoproteins

EJ Schaefer, DW Anderson, LA Zech, FT Lindgren, TB Bronzert, EA Rubalcaba and HB Brewer Jr

The metabolism of apolipoproteins A-I and A-II, as well as other high density lipoprotein (HDL) constituents, was studied in patients with homozygous familial HDL deficiency (Tangier disease) prior to and after plasma exchange or HDL infusion. Mean plasma apoA-I, apoA-II, and HDL cholesterol values in homozygotes (n = 2) were 2.0 mg/dl, 2.7 mg/dl, and 1.5 mg/dl, respectively, and in a normal control subject were 125.1 mg/dl, 23.0 mg/dl, and 53.0 mg/dl, respectively. Based on radioiodinated apoA-I and apoA-II kinetic studies in the baseline state, synthesis rates for apoA-I and apoA-II in mg/kg/day were 3.81 and 1.61, respectively, in one homozygote (patient B) and 11.82 and 1.99, respectively, in the normal subject. ApoA-I and apoA-II plasma residence times in days were 0.22 and 0.81, respectively, in the homozygote, and 4.04 and 4.44, respectively, in the normal subject. These data indicate that this homozygote had both a moderate decrease in the synthetic rates of apoA-I and apoA-II, as well as a marked decrease in the plasma residence times of these two apolipoproteins. In one homozygote (patient A) following a complete plasma exchange during cardiopulmonary bypass, plasma HDL cholesterol, apoA-I, and apoA-II levels were very similar to pre-exchange values within 64 hr after exchange. A second homozygote (patient B) received HDL intravenously as well as 125I-labeled apoA-I and 131I-labeled apoA-II. Following infusion, the residence time in days for HDL subfractions, HDL2b, HDL2a, and HDL3 were 0.1, 0.8, and 2.7, respectively. HDL protein and phospholipid both had a monoexponential decay, with residence times of 0.7 days, while HDL triglyceride disappeared monoexponentially with a residence time of 0.5 days. HDL cholesterol had a biexponential decay, with the residence time of the slow component being 0.7 days. Plasma and HDL apoA-I decayed down to baseline values significantly faster than did plasma and HDL apoA-II. ApoA-II specific radioactivity decreased throughout the course of the infusion study in both plasma and HDL, while apoA-I specific radioactivity decreased slightly, then rose, and subsequently declined in both plasma and HDL. The data indicate that the rapid and altered catabolism of apoA-I and apoA-II in Tangier homozygotes persists despite major increases in the plasma pool size of these proteins. In addition, following HDL infusion, HDL2b and HDL2a disappeared at a faster rate than HDL3, HDL cholesterol and triglyceride were catabolized at a faster rate than HDL protein and phospholipid, and apoA-I disappeared more rapidly than apoA-II. These observations may have important implications with regard to the catabolism of HDL subfractions and constituents in normal man.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. R. Singaraja, B. Stahmer, M. Brundert, M. Merkel, J. Heeren, N. Bissada, M. Kang, J. M. Timmins, R. Ramakrishnan, J. S. Parks, et al. Hepatic ATP-Binding Cassette Transporter A1 Is a Key Molecule in High-Density Lipoprotein Cholesteryl Ester Metabolism in Mice Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1821 - 1827. [Abstract] [Full Text] [PDF]

				S. E. Wahrle, H. Jiang, M. Parsadanian, R. E. Hartman, K. R. Bales, S. M. Paul, and D. M. Holtzman Deletion of Abca1 Increases Abeta Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease J. Biol. Chem., December 30, 2005; 280(52): 43236 - 43242. [Abstract] [Full Text] [PDF]

				J.-Y. Lee, J. M. Timmins, A. Mulya, T. L. Smith, Y. Zhu, E. M. Rubin, J. W. Chisholm, P. L. Colvin, and J. S. Parks HDLs in apoA-I transgenic Abca1 knockout mice are remodeled normally in plasma but are hypercatabolized by the kidney J. Lipid Res., October 1, 2005; 46(10): 2233 - 2245. [Abstract] [Full Text] [PDF]

				S. E. Wahrle, H. Jiang, M. Parsadanian, J. Legleiter, X. Han, J. D. Fryer, T. Kowalewski, and D. M. Holtzman ABCA1 Is Required for Normal Central Nervous System ApoE Levels and for Lipidation of Astrocyte-secreted apoE J. Biol. Chem., September 24, 2004; 279(39): 40987 - 40993. [Abstract] [Full Text] [PDF]

				C.-A. Wu, M. Tsujita, M. Hayashi, and S. Yokoyama Probucol Inactivates ABCA1 in the Plasma Membrane with Respect to Its Mediation of Apolipoprotein Binding and High Density Lipoprotein Assembly and to Its Proteolytic Degradation J. Biol. Chem., July 16, 2004; 279(29): 30168 - 30174. [Abstract] [Full Text] [PDF]

				T. G. Vishnyakova, A. V. Bocharov, I. N. Baranova, Z. Chen, A. T. Remaley, G. Csako, T. L. Eggerman, and A. P. Patterson Binding and Internalization of Lipopolysaccharide by Cla-1, a Human Orthologue of Rodent Scavenger Receptor B1 J. Biol. Chem., June 13, 2003; 278(25): 22771 - 22780. [Abstract] [Full Text] [PDF]

				R. S. Kiss, D. C. McManus, V. Franklin, W. L. Tan, A. McKenzie, G. Chimini, and Y. L. Marcel The Lipidation by Hepatocytes of Human Apolipoprotein A-I Occurs by Both ABCA1-dependent and -independent Pathways J. Biol. Chem., March 14, 2003; 278(12): 10119 - 10127. [Abstract] [Full Text] [PDF]

				J. W. Chisholm, E. R. Burleson, G. S. Shelness, and J. S. Parks ApoA-I secretion from HepG2 cells: evidence for the secretion of both lipid-poor apoA-I and intracellularly assembled nascent HDL J. Lipid Res., January 1, 2002; 43(1): 36 - 44. [Abstract] [Full Text] [PDF]

				J. F. Oram and R. M. Lawn ABCA1: the gatekeeper for eliminating excess tissue cholesterol J. Lipid Res., August 1, 2001; 42(8): 1173 - 1179. [Abstract] [Full Text] [PDF]

				M. E. Brousseau, G. P. Eberhart, J. Dupuis, B. F. Asztalos, A. L. Goldkamp, E. J. Schaefer, and M. W. Freeman Cellular cholesterol efflux in heterozygotes for Tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size J. Lipid Res., July 1, 2000; 41(7): 1125 - 1135. [Abstract] [Full Text]

				A. R. Tall and C. W. Schindler A, B, C...{gamma}! Arterioscler. Thromb. Vasc. Biol., June 1, 2000; 20(6): 1423 - 1424. [Full Text] [PDF]

				M. E. Brousseau, E. J. Schaefer, J. Dupuis, B. Eustace, P. Van Eerdewegh, A. L. Goldkamp, L. M. Thurston, M. G. FitzGerald, D. Yasek-McKenna, G. O'Neill, et al. Novel mutations in the gene encoding ATP-binding cassette 1 in four Tangier disease kindreds J. Lipid Res., March 1, 2000; 41(3): 433 - 441. [Abstract] [Full Text]

				A. T. Remaley, S. Rust, M. Rosier, C. Knapper, L. Naudin, C. Broccardo, K. M. Peterson, C. Koch, I. Arnould, C. Prades, et al. Human ATP-binding cassette transporter 1 (ABC1): Genomic organization and identification of the genetic defect in the original Tangier disease kindred PNAS, October 26, 1999; 96(22): 12685 - 12690. [Abstract] [Full Text] [PDF]

				A.T. Remaley, U.K. Schumacher, J.A. Stonik, B.D. Farsi, H. Nazih, and H.B. Brewer Decreased Reverse Cholesterol Transport from Tangier Disease Fibroblasts : Acceptor Specificity and Effect of Brefeldin on Lipid Efflux Arterioscler. Thromb. Vasc. Biol., September 1, 1997; 17(9): 1813 - 1821. [Abstract] [Full Text]